LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (drug combination treatments). Dataset 1 of 2: Cell count and normalized growth rate inhibition values. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (drug combination treatments). Dataset 1 of 2: Cell count and normalized growth rate inhibition values. - Dataset (ID:20259)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 29 of 139
Next
>>
>
701 to 725 of 3455 records
per page:

Cell	Small Molecule	Small Mol 1 Concentration	Small Mol 1 Conc Unit	Small Molecule 2	Small Mol 2 Concentration	Small Mol 2 Conc Unit	Biological Replicate	Technical Replicate	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Normalized Growth Rate Inhibition Value
BT-20	Dactolisib	0.0047	uM	Neratinib	0.3704	uM	1	2	2751	3613	4996	0.3724
BT-20	Dactolisib	0.0412	uM	Selumetinib	0.1235	uM	1	2	2751	1983	4996	-0.3164
BT-20	Alpelisib	0.1235	uM	Trametinib	0.1235	uM	1	2	2751	4624	4996	0.8279
BT-20	Alpelisib	1.1111	uM	Trametinib	0.1235	uM	1	2	2751	2134	4996	-0.2555
BT-20	Alpelisib	3.3333	uM	NVP-TAE684	1.1111	uM	1	2	2751	984	4996	-0.6971
BT-20	Neratinib	0.6415	uM		0	uM	1	2	2751	4043	4996	0.5639
BT-20	Alpelisib	0.0400	uM	Selumetinib	3.3333	uM	1	2	2751	4463	4996	0.7541
BT-20	Dactolisib	0.1235	uM	Saracatinib	0.6415	uM	1	2	2751	1222	4996	-0.6104
BT-20	Alpelisib	0.1235	uM	Neratinib	1.1111	uM	1	2	2751	2599	4996	-0.0639
BT-20	Alpelisib	0.1235	uM	Selumetinib	0.3704	uM	1	2	2751	4534	4996	0.7866
BT-20	Alpelisib	0.1235	uM	Trametinib	0.3704	uM	1	2	2751	3738	4996	0.4277
BT-20	Dactolisib	0.1235	uM	NVP-TAE684	0.3704	uM	1	2	2751	2157	4996	-0.2462
BT-20	Alpelisib	3.3333	uM	Lapatinib	1.9245	uM	1	2	2751	624	4996	-0.8215
BT-20	Dactolisib	0.0412	uM	Trametinib	10	uM	1	2	2751	936	4996	-0.7142
BT-20	Alpelisib	0.1235	uM	Neratinib	0.6415	uM	1	2	2751	3228	4996	0.2040
BT-20	Alpelisib	0.3704	uM	NVP-TAE684	1.1111	uM	1	2	2751	4383	4996	0.7177
BT-20	Dactolisib	0.0137	uM	Saracatinib	1.9245	uM	1	2	2751	2934	4996	0.0776
BT-20	Dactolisib	0.3704	uM	Saracatinib	1.1111	uM	1	2	2751	1194	4996	-0.6208
BT-20	Dactolisib	0.3704	uM	Lapatinib	1.1111	uM	1	2	2751	1377	4996	-0.5524
BT-20	Dactolisib	0.0047	uM	Saracatinib	1.1111	uM	1	2	2751	3810	4996	0.4597
BT-20	Dactolisib	0.0412	uM	NVP-TAE684	0.3704	uM	1	2	2751	2463	4996	-0.1206
BT-20	Dactolisib	0.0137	uM	Trametinib	10	uM	1	2	2751	1173	4996	-0.6285
BT-20	Alpelisib	0.3704	uM	Trametinib	10	uM	1	2	2751	1756	4996	-0.4064
BT-20	Dactolisib	0.0047	uM	Neratinib	0.2138	uM	1	2	2751	3502	4996	0.3235
BT-20	Dactolisib	0.0047	uM		0	uM	1	2	2751	4604	4996	0.8187

|<
<<
Previous
Page 29 of 139
Next
>>
>
701 to 725 of 3455 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (drug combination treatments). Dataset 1 of 2: Cell count and normalized growth rate inhibition values. - Dataset (ID:20259)